GlycoMimetics has been granted a patent for compounds and methods to treat diseases by inhibiting E-selectin binding. The patent includes glycomimetic E-selectin antagonists. GlobalData’s report on GlycoMimetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights GlycoMimetics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on GlycoMimetics, Cancer treatment biomarkers was a key innovation area identified from patents. GlycoMimetics's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment and prevention of diseases by inhibiting e-selectin binding

Source: United States Patent and Trademark Office (USPTO). Credit: GlycoMimetics Inc

The granted patent (Publication Number: US11878026B2) pertains to compounds known as glycomimetic E-selectin antagonists, as outlined in the claims. These compounds are designed to inhibit E-selectin mediated functions, which are crucial in various disease conditions. The patent covers the use of these compounds in compositions along with other pharmaceutically acceptable ingredients for therapeutic purposes.

Furthermore, the patent details methods for administering these compounds to individuals in need, targeting a range of conditions such as inflammatory diseases and cancer. Specifically, the patent highlights the potential applications in inhibiting cancer metastasis, preventing infiltration of cancer cells into vital organs, and enhancing the survival of hematopoietic stem cells. The methods described also include combining the compound with traditional cancer therapies like chemotherapy and radiotherapy for improved outcomes. Overall, the patent underscores the versatility and potential of these glycomimetic E-selectin antagonists in addressing various disease states where E-selectin inhibition is beneficial.

To know more about GlobalData’s detailed insights on GlycoMimetics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies